These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 34884975

  • 1. (20S) Ginsenoside Rh2 Exerts Its Anti-Tumor Effect by Disrupting the HSP90A-Cdc37 System in Human Liver Cancer Cells.
    Chen C, Wang YS, Zhang ET, Li GA, Liu WY, Li Y, Jin YH.
    Int J Mol Sci; 2021 Dec 06; 22(23):. PubMed ID: 34884975
    [Abstract] [Full Text] [Related]

  • 2. (20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2.
    Wang YS, Chen C, Zhang SY, Li Y, Jin YH.
    Int J Mol Sci; 2021 Aug 27; 22(17):. PubMed ID: 34502195
    [Abstract] [Full Text] [Related]

  • 3. The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.
    Wang YS, Lin Y, Li H, Li Y, Song Z, Jin YH.
    Sci Rep; 2017 Sep 29; 7(1):12408. PubMed ID: 28963461
    [Abstract] [Full Text] [Related]

  • 4. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
    Wang Z, Wei W, Sun CK, Chua MS, So S.
    Liver Int; 2015 Apr 29; 35(4):1403-15. PubMed ID: 25098386
    [Abstract] [Full Text] [Related]

  • 5. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.
    Hallett ST, Pastok MW, Morgan RML, Wittner A, Blundell KLIM, Felletar I, Wedge SR, Prodromou C, Noble MEM, Pearl LH, Endicott JA.
    Cell Rep; 2017 Oct 31; 21(5):1386-1398. PubMed ID: 29091774
    [Abstract] [Full Text] [Related]

  • 6. Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.
    Qiang SQ, Qin GC, Jing L, Qiang FZ, Mei QH, Long CD.
    Asian Pac J Cancer Prev; 2021 Aug 01; 22(8):2529-2539. PubMed ID: 34452568
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.
    Lv Q, Rong N, Liu LJ, Xu XL, Liu JT, Jin FX, Wang CM.
    Planta Med; 2016 May 01; 82(8):705-11. PubMed ID: 27163230
    [Abstract] [Full Text] [Related]

  • 11. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
    Li Q, Li B, Dong C, Wang Y, Li Q.
    Eur J Pharmacol; 2017 Nov 15; 815():173-180. PubMed ID: 28928088
    [Abstract] [Full Text] [Related]

  • 12. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression.
    Chung KS, Cho SH, Shin JS, Kim DH, Choi JH, Choi SY, Rhee YK, Hong HD, Lee KT.
    Carcinogenesis; 2013 Feb 15; 34(2):331-40. PubMed ID: 23125221
    [Abstract] [Full Text] [Related]

  • 13. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
    Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, Yu XD.
    Mol Cancer; 2011 Aug 29; 10():104. PubMed ID: 21871133
    [Abstract] [Full Text] [Related]

  • 14. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
    Huang W, Ye M, Zhang LR, Wu QD, Zhang M, Xu JH, Zheng W.
    Mol Cancer; 2014 Jun 14; 13():150. PubMed ID: 24927996
    [Abstract] [Full Text] [Related]

  • 15. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
    Eguchi T, Sogawa C, Ono K, Matsumoto M, Tran MT, Okusha Y, Lang BJ, Okamoto K, Calderwood SK.
    Cells; 2020 Mar 19; 9(3):. PubMed ID: 32204513
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases.
    Choi S, Kim TW, Singh SV.
    Pharm Res; 2009 Oct 19; 26(10):2280-8. PubMed ID: 19629651
    [Abstract] [Full Text] [Related]

  • 18. Atomistic simulations and network-based modeling of the Hsp90-Cdc37 chaperone binding with Cdk4 client protein: A mechanism of chaperoning kinase clients by exploiting weak spots of intrinsically dynamic kinase domains.
    Czemeres J, Buse K, Verkhivker GM.
    PLoS One; 2017 Oct 19; 12(12):e0190267. PubMed ID: 29267381
    [Abstract] [Full Text] [Related]

  • 19. Pseudo-ginsenoside Rh2 Induces Protective Autophagy in Hepatocellular Carcinoma HepG2 Cells.
    Zhang F, Xu H, Xia R, Yu P, Li Y, Yu X, Sui D.
    Recent Pat Anticancer Drug Discov; 2021 Oct 19; 16(4):521-532. PubMed ID: 34109916
    [Abstract] [Full Text] [Related]

  • 20. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.
    Stepanova L, Leng X, Parker SB, Harper JW.
    Genes Dev; 1996 Jun 15; 10(12):1491-502. PubMed ID: 8666233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.